Thrombophilic state in breast cancer

Area of Science:

• Oncology
• Hematology
• Pharmacology

Background:

• Tumor cell metastasis and thrombosis are leading causes of cancer patient mortality.
• Cancer itself can induce a hypercoagulable state, increasing thrombosis risk.
• Tumor cells and comorbid factors (surgery, infection, certain drugs) contribute to thrombosis.

Purpose of the Study:

• To review the literature on the effects of chemotherapy and hormone therapy on blood clotting factors in cancer patients.
• To emphasize new developments in tissue-specific selective estrogen receptor modulators (SERMs).
• To assess the thromboembolic risk associated with cancer treatments.

Main Methods:

• Literature review of studies on cancer, thrombosis, and treatment-related risks.
• Analysis of the impact of chemotherapy and hormone therapy on coagulation.
• Focus on selective estrogen receptor modulators (SERMs) and their role.

Main Results:

• Chemo- and/or hormone therapy in breast cancer patients increases thromboembolic risk.
• The benefits of cancer treatment generally outweigh the associated thromboembolic risks.
• Selective estrogen receptor modulators (SERMs) show promise in breast cancer therapy and other applications.

Conclusions:

• Thrombosis is a significant concern in cancer patients, influenced by malignancy and treatments.
• Understanding the interplay between cancer therapies and coagulation is crucial for patient management.
• Selective estrogen receptor modulators (SERMs) represent a developing area with potential therapeutic applications in oncology and beyond.